M-A: Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization.

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Related:

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

Bayesian SRMA of 3 RCTs showed a high prob (94-98.6%) that fluvoxamine is associated with reduced risk of hospitalization for outpatients with #COVID19, (RR 0.75). @DrEmilyMcD @DrToddLee @simonevigod @AngelaReiersen @boulware_dr https://t.co/ctMKzBDbzP

— JAMA Network Open (@JAMANetworkOpen) April 6, 2022